Please login to the form below

Not currently logged in
Email:
Password:

Biogen expands digital safety platform Assessa

The MS technolgy pilot, a collaboration with Ixico, will now include pharmacoviglance reporting

BrainBiogen has expanded work on its digital safety platform, which helps monitor MS patients for signs of the rare and potentially fatel brain infection progressive multifocal leukoencephalopathy (PML).

The pilot programme, a collaboration with tech firm Ixico, will now include pharmacoviglance reporting to monitor patients for previously unreported adverse reactions.

The partners - who have been in a collaborative agreement since October 2015 - developed the Assessa system to provide neurologists with second opinion reading services if there is a suspicion of PML.

Giulio Cerroni, chief executive officer of Ixico, said: “We are delighted to announce the expansion of this pilot involving clinical experts in specialist MS centres and Biogen.

“The Assessa PML digital platform is intended to provide technology and speciality services to physcians involved in delivering care to people living with MS.”

Biogen has invested £1.5m in the project, which is currently being piloted in five EU countries.

Article by
Gemma Jones

11th August 2017

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Cutting through the noise
AstraZeneca looks to lead an R&D revolution as the company invests in CRISPR and functional genomics drug discovery...
International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...

Infographics